News

EU fuels synthetic biology
Enlarge image

FundingEU

EU fuels synthetic biology

15.05.2013 - Funding agencies from 13 European countries have kicked off a €15.5m initiative for synthetic biology.

The funding call is the first one of the ERA-Net SynBio, a network of 16 national funding agencies that kicked off in 2012 and wants to boost cross-border collaborations in synthetic biology. Funding topics will range from metabolic engineering for sustainable chemistry over regulatory circuits to provide new functions in cells and organisms to so-called orthogonal biosystems, which express genes and proteins with completely new functions. Furthermore the funding will go into components for cell-based machines or cell-free devices to perform complex new tasks, microorganisms with minimal genomes, and synthetic protocells.

Each proposal must involve a minimum of three partners from at least three different European funding countries. Consortia involving US-partners must involve partners from a minimum of four countries.

ERASynBio, which launched last year, also seeks to stimulate collaborations between academia and industry and integrate them into focused research projects, and by providing training opportunities and creating an interdisciplinary advisory board.

"Synthetic biology has the potential to address some of the major challenges of the 21st century as well as offering innovations to benefit the economy“, said BBSRC Chief Executive Douglas Kell. „By applying engineering principles to biological research we have the potential to shape the future of industrial compounds, biofuels and new medicines, and to provide exciting insights into fundamental biological mechanisms."

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/eu-fuels-synthetic-biology.html

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.22 EUR0.00%
  • ACTELION111.20 CHF0.00%
  • ADDEX3.98 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.22 EUR0.00%
  • ACTELION111.20 CHF0.00%

TOP

  • SANTHERA98.35 CHF64.2%
  • BB BIOTECH141.00 EUR9.0%
  • EPIGENOMICS3.37 EUR5.3%

FLOP

  • WILEX2.25 EUR-16.7%
  • MOLOGEN7.38 EUR-13.2%
  • BIOFRONTERA2.40 EUR-10.4%

TOP

  • SANTHERA98.35 CHF4310.3%
  • CO.DON2.48 EUR210.0%
  • PAION2.43 EUR173.0%

FLOP

  • CYTOS0.25 CHF-93.7%
  • MEDIGENE4.55 EUR-67.3%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 30.08.2014